Biologics manufacturing and nonclinical services

Active Awarded Last action

Contract number
75N95022D00023
Awardee
Awarding agency
Task orders
4 $13,924,303 obligated

Award facts

Opportunity
  • 75N95022R00013 Solicitation number
Combined order value
  • $13,924,303 Current, with exercised options
  • $22,860,481 Potential, with all options
Last date to order 51% complete
IDV ceiling 9% used
$149,200,000.00
Award type
Multiple award
Who can order
Only the awarding agency
Funding agency
National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
Set-aside
No set-aside
Competition
Full and Open Competition · 3 offers Negotiated Proposal / Quote
Pricing
Order Dependent (IDV only)
Legislative mandates

Award details come from SAM.gov/FPDS.

About this IDV

The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), has awarded Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods, an Indefinite Delivery Contract (IDC) valued at $149.2 million. The purpose of this contract is to provide manufacturing and nonclinical studies support for the development of therapeutic biotechnology products for neurological-related disorders. Under this IDC, NINDS has issued several delivery orders to ABL, including a $5.7 million order for lead candidate identification, pharmacology, and toxicology studies for an antibody project in NINDS's Blueprint Neurotherapeutics (BPN) Biologics Program, a $6 million order for the manufacture and preclinical testing of site blocking oligonucleotides, a $21,326 order for a contract kickoff meeting and project management plan, and a $13 million order for the cGMP manufacture of VHCA8* for the treatment of pain. These task orders demonstrate ABL's broad capabilities in supporting the development of vaccines, therapeutics, and diagnostics across various neurological disease areas through its work with federal health agencies.

Task orders

Transactions

Action Obligated Date
Other Administrative Action P00003 · Biologics manufacturing and nonclinical services - biologics manufacturing and nonclinical services $0
Supplemental Agreement for work within scope P00002 $0
Other Administrative Action P00001 $0
Original award $0

Quick answers

Who was awarded contract 75N95022D00023?

75N95022D00023 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 28, 2022.

How much is contract 75N95022D00023 worth?

Orders under 75N95022D00023 have obligated $13,924,303. Their combined potential value, with all options, is $22,860,481. 75N95022D00023's own ceiling is $149,200,000.

How many orders have been placed under contract 75N95022D00023?

4 orders have been placed under 75N95022D00023, the latest on July 19, 2024.

Which agency awarded contract 75N95022D00023?

National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022D00023, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).

Who can order from contract 75N95022D00023?

75N95022D00023 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.

Is contract 75N95022D00023 part of a contract vehicle?

Yes. 75N95022D00023 is part of Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders.

Was contract 75N95022D00023 competed?

The extent of competition for 75N95022D00023 was full and open competition. The government received 3 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV